Comparison of first-quarter results of the top 10 U.S. pharmaceutical companies in 2018

Pfizer said first-quarter earnings rose to $3.56 billion, compared with $3.12 billion a year earlier. Revenue rose to $12.91 billion from $12.78 billion.First Quarter earnings fell to $736m, compared with $1.55bn a year earlier. The company's costs associated with its partnership with Eisai were $1.4 billion. Revenue rose to $10.04 billion from $9.43 billion.and consumer goods company Johnson and Johnson announced first-quarter results. Net profit fell to $4.37 billion from $4.42 billion a year earlier. Revenue rose 12.6 percent to $20.01 billion, with consumer, pharmaceutical and medical equipment revenues rising and exceeding expectations.AbbVie reported better-than-expected first-quarter profit and revenue. Profit rose to $2.78 billion in the quarter from $1.71 billion a year earlier. Revenue rose to $7.93 billion from $6.54 billion. Sales at Symele, Imbruvica, Lupron, Creon, Synagis, AndroGel, Duodopa and Sevoflurane were higher than expected, while sales at Synthroid and Kaletra were lower than expected., the drugmaker, turned a net profit of $1.22bn in the first quarter, compared with a loss of $110.8m a year earlier. Revenue rose to $5.70 billion from $5.23 billion.Agen posted a first-quarter profit of $2.31 billion, compared with $2.07 billion a year earlier. Adjusted earnings for one-time items were $2.46 billion, compared with $2.33 billion a year earlier. Sales rose 2 percent to $5.55 billion from $5.46 billion a year earlier.Bristol-Myers Squibb said first-quarter earnings fell to $1.49 billion, compared with $1.57 billion a year earlier. Revenue rose to $5.19 billion from $4.93 billion. Opdivo, Eliquis and Orencia reported better-than-expected sales, while Springcel, Yervoy and Empliciti reported lower-than-expected sales., the drugmaker, posted a first-quarter net profit of $1.54 billion, compared with $2.7 billion a year earlier. Revenue fell to $5.09 billion from $6.51 billion a year earlier.Celgene said first-quarter earnings fell to $846 million, compared with $932 million a year earlier. Revenue rose to $3.538 billion from $2,962 million. Revlimid, Pomalyst, Otezla, Abraxane and Vidaza all had better-than-expected sales. The company completed its acquisition of juno, a biotech company, in March.Inc. rose to $1.2 billion in the first quarter from $748 million a year earlier. Revenue rose to $3.13 billion from $2.81 billion. (Global Enterprise Dynamics)